17,261 trials
Carcinoma, Non-Small-Cell Lung
Primary: Part D: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 15; 13 Participants
Non-Small Cell Lung Cancer
Primary: Progression Free Survival by BICR
HIV Infection
Primary: Occurrence of Grade ≥ 1 Adverse Events (AEs) — 5; 26; 4 events
Schizophrenia
Primary: Change From Baseline on the PANSS NSFS at Week 12 — -3.1; -3.3; -3.4; -2.5 scores on a scale — p=0.426
Short Stature
Primary: Height Velocity — 3.0; 4.3; 6.2; 4.8 cm/y
FLT3 Gene Mutation Negative · FLT3 Internal Tandem Duplication Positive · Recurrent Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose of Quizartinib (Phase I) — 60; 60 Milligrams
Schizophrenia
Primary: Change From Baseline in Average Percent of Conditioned Responses During the Eye Blink Conditioning (EBC) Test at Day 8 — 0.597; 0.319; 0.578; 1.344 Percent of…
Meibomian Gland Dysfunction · Dry Eye
Primary: Meibomian Glands Yielding Liquid Secretion (MGYLS) — -0.7; 3.41; 3.07; 1.88 Number of Open Glands
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Breast Cancer
Primary: Time to Treatment Failure (TTF) Compared Between Treatment Groups. — 5.7; 8.3 months
Confirmed Genetic Diagnosis of Prader-Willi Syndrome
Primary: Percent Change From Baseline to End of Treatment in Mean Body Weight — -4.09; -0.38; 3.56; 3.00 Percent (%) change in mean body weight — p=0.1045
Adeno-Associated Virus (AAV) · Blood Coagulation Disorder · Blood Coagulation Disorders, Inherited
Primary: Number of Participants With Adverse Events (AEs) — 4 Participants
Breast Cancer
Primary: Percentage of Participants Exhibiting a Pathological Complete Response (pCR) in Breast — 41.3; 54.0 percentage of participants — p=0.154
Metastatic Triple Negative Breast Cancer
Primary: Objective Response Rate (ORR) — 0; 1; 1; 4 Participants
Colorectal Adenocarcinoma
Primary: Percentage of Patients With a Tumoral Control Rate at 2 Months — 31.4 Percentage of patients